Shanghai Pharmaceuticals Holding (601607.SH): Approval for production of Diprophylline Injection.

15:36 26/03/2026

Shanghai Pharmaceuticals (601607.SH) announced that recently, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Shanghai Hefeng"), a subsidiary of the company, received the "Drug Registration Certificate" (Certificate No.: 2026S00781) issued by the National Medical Products Administration for its hydroxypropyl theophylline injection, which has been approved for production.

Shanghai Pharmaceuticals Holding (601607.SH) announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd. (referred to as "Shanghai Hefeng"), recently received a "Drug Registration Certificate" (Certificate Number: 2026S00781) issued by the National Medical Products Administration for its hydroxypropyl theophylline injection. This drug has been approved for production. Hydroxypropyl theophylline injection is used to relieve asthma, asthmatic bronchitis, obstructive pulmonary emphysema, and other respiratory symptoms. It can also be used for asthma caused by cardiogenic pulmonary edema.

Sinolink: Escalation of US-Iran conflict reverses "weak US dollar" narrative, strong assets may help reverse market decline and indicate a bottom.

Huachuang Securities: Under the impact of high oil prices in this round, the middle and upper reaches of the profit margin may have more resilience.

Hua Chuang Securities' Zhang Yu: High oil prices bring "clearing out," China's midstream market share may "rise"

Sinolink: Escalation of US-Iran conflict reverses "weak US dollar" narrative, strong assets may help reverse market decline and indicate a bottom.

Huachuang Securities: Under the impact of high oil prices in this round, the middle and upper reaches of the profit margin may have more resilience.

Hua Chuang Securities' Zhang Yu: High oil prices bring "clearing out," China's midstream market share may "rise"